# 1. Financial Performance ## A. Key Figures * **Revenue:** ₹579 Cr H1 FY26 (+26%) · ₹295 Cr Q2 FY26 (+26%) * **EBITDA:** ₹108 Cr H1 FY26 (+53%) · ₹54 Cr Q2 FY26 (+6%) * **PAT:** ₹67 Cr H1 FY26 (+48%) · ₹32 Cr Q2 FY26 (+22%) * EBITDA Margin: 18.6% H1 FY26; Q2 margin not specified but aligned with 18%-20% guidance * **Net Cash Balance:** **₹80 Cr** (debt-free balance sheet) ## B. Revenue Growth * **Sustained Top-Line Momentum:** Revenue grew 26% YoY in H1 and Q2, driven by strong export performance and resilience in core business segments. * **Sequential Recovery:** Consolidated revenue increased QoQ from ₹275 Cr to ₹290 Cr, led by export strength despite flat reported profitability. ## C. Profit Margins * **Margin Expansion Underway:** EBITDA margins improved to ~18–19% in H1 and Q2, reflecting operational discipline, cost efficiencies, and favorable impact from antidumping duties on key products. * **Capital Efficiency Improving:** Return on capital employed rose to 8% in Q2 from 6% a year ago, signaling better asset utilization and operating leverage. * **Structural Margin Support:** Management expects H2 margins to sustain within the 18–20% range, supported by cost competitiveness, stable production efficiencies, and high-margin sales base. ## D. Balance Sheet * **Strong Liquidity Position:** Company remains debt-free with a healthy net cash balance, funding growth entirely through internal accruals. ## E. Cash Flow * **Working Capital Transformation:** Working capital days reduced sharply from 255 to 174 days in six months; management targets further reduction of 25–30 days in cash conversion cycle by March 2026. * **Clarification on Financing:** ₹16 Cr in consolidated financing activities relates to subsidiary-level long-term borrowings, not IPO proceeds. --- # 2. Export & Domestic Sales ## A. Key Figures * **Export Revenue:** **₹140 Cr** (Q2 FY26) (+89% YoY) · **₹74 Cr** (Q2 FY25) * **Domestic Revenue:** **₹150 Cr** (Q2 FY26) ## B. Export Growth * **Robust International Expansion:** Export sales nearly doubled with strong momentum across Europe, Australia, and the U.S., driven by rising global demand and increased customer inquiries. * **Product & Market Strategy:** Growth fueled by technical materials and **customized bulk formulations**, reflecting strategic positioning as a B2B solutions provider rather than a branded formulator. * **Policy Tailwinds & Outlook:** Favorable government policies supporting exports and strong order flow signal sustained momentum, with expectations of further strength in H2. ## C. Domestic Resilience * **Stable Performance Amid Weather Challenges:** Domestic sales held firm despite monsoon-related pest infestation declines, outperforming peers and demonstrating pricing power and market share resilience. * **Seasonal Revenue Pattern:** Company follows typical agrochemical seasonality with **~55% of annual turnover in H1**, primarily driven by domestic Kharif demand. ## D. Sales Mix * **Strategic Mix Target Maintained:** Despite current export surge, management continues to target a **55–60% domestic / 40–45% export** revenue split, balancing geographic diversification with core market focus. * **H2 Revenue Support:** Exports play a critical role in offsetting seasonal domestic softness during the Rabi-only season in H2. --- # 3. Product & Segment Mix ## A. Key Figures * **Revenue Mix (Q2 FY26):** 66% technical & API · 34% formulations * **EBITDA Margin:** ~19% technical grade · ~16% formulated products (100–150 bps lower) * **Pretilachlor Sales:** ₹55 Cr in Q1 (seasonal peak) ## B. Technical vs Formulation * **Technical Production Scaling:** Initial technical-grade molecule production underway; expansion to include more molecules in current and next fiscal despite infrastructure delays. * **Formulation Momentum:** Recent surge in bulk formulation sales is sustainable and expected to be repetitive, driven by customer cost-efficiency preferences, with facility expansions underway to meet demand. ## C. New Molecule Launches * **Pipeline Progress:** At least two of three off-patent molecules to launch next year via Shalvis Specialities, with lab and pilot-scale conditions optimized. * **Differentiated Product Strategy:** Focus on launching higher-margin, less competitive products in Shalvis, backed by customer agreements enabling immediate sales post-production. * **Margin Outlook:** New differentiated products targeted at **18–20% average margins**, signaling potential uplift in overall profitability. ## D. Revenue by Product Type * **Formulation Growth Trend:** Formulation share rose to 34% in Q2 from 27–28% annually last year, expected to remain slightly higher due to sustained bulk demand. * **Seasonal Sales Pattern:** Pretilachlor sales are heavily front-loaded, with minimal to no contribution expected in Q2 and beyond, aligning with agricultural demand cycles. --- # 4. Capacity & Utilization ## A. Key Figures * **Technical Utilization:** **>73%** in H1 FY26 (improvement YoY) * **Formulation Capacity:** **6,500 → 10,000 MTPA** (+54% expansion) * **Revenue from Expansion Projects:** **INR 400 Cr** expected at full utilization (formulation) · **INR 250–300 Cr** from PEDA at 75% utilization · **~INR 100 Cr** from Shalvis next year ## B. Plant Utilization * **Operational Ramp-Up Accelerating:** PEDA plant nearing commissioning, expected online in **15–20 days**, with full utilization anticipated by next year despite monsoon delays. * **Shalvis Project Reaching Milestones:** One technical-grade block nearing commissioning; pilot plant already producing, signaling progress in specialty chemical scaling. ## C. Expansion Projects * **Strategic Scaling on Track:** Formulation capacity expansion and **2,6-DEA backward integration at Sandila** progressing as planned, supporting long-term margin and supply chain resilience goals. * **Growth-Funded Expansion:** Ongoing investments in subsidiaries to continue, with recent **INR 16 Cr** equity infusion reflecting sustained capital allocation toward capacity buildout. ## D. Backward Integration * **Self-Sufficiency Drive:** Backward integration projects targeting **full coverage of internal raw material needs**, reducing import reliance and securing margins for forward-integrated products. * **Margin Resilience Confirmed:** Management reaffirms **18–20% EBITDA margin** target range, underpinned by integration benefits and operational scale. --- # 5. Strategic Initiatives ## A. CR-DMO Progress * **Strategic Partnerships Advancing:** CR-DMO initiatives gaining traction with active discussions underway with multiple global innovators, signaling growing recognition of IPL’s R&D and manufacturing capabilities. * **Integrated Model Driving Value:** Fully integrated manufacturing chain and continuous operational improvements underpin sustainable growth and long-term stakeholder returns. ## B. Global Customer Engagement * **Export-Led Growth Accelerating:** Sharp focus on international markets—especially Australia, Europe, North and South America—driving export expansion and deepening global customer relationships. * **Strong International Demand Recovery:** Key markets including Europe, U.S.A., Japan, and Australia show normalized inventories and a robust order book, supporting near-term revenue visibility. * **Proactive Engagement Fueling Orders:** Direct customer outreach, including on-site visits worldwide, is strengthening trust and converting into secured business. * **Self-Funded Global Expansion:** Growth fully financed through internal accruals, with enhanced investor outreach planned to improve market recognition and valuation. ## C. Atmanirbhar Bharat Focus * **Backward Integration Enhancing Margins:** Strategic capex execution and R&D-led innovation are enabling scale-up of high-value differentiated molecules, with integrated production boosting margin potential. * **Domestic Manufacturing Deepening:** Strong progress in import substitution—highlighted by **PEDA**, now **100% domestically produced** versus >90% imported from China—underscores India’s growing self-reliance. * **Reinvestment Over Buybacks:** Management prioritizes long-term value creation, opting to reinvest surplus capital into capacity and assets rather than returning it via buybacks. --- # 6. Risks & Regulatory Exposure ## A. Key Figures * **Sales Returns:** **5% to 6%** of sales in Crop Protection (normal range) * **Registration Costs:** **₹7–8 L** per Indian technical registration · **₹25–30 K** per Indian formulation · **₹25 L** per export registration ## B. Monsoon Dependence * **Favorable Rabi Outlook:** Extended monsoon has improved soil moisture and sowing conditions, supporting strong domestic demand expectations in H2. * **Resilience Amid Industry Challenges:** Company outperformed peers despite adverse weather impacts on agrochemical demand, reflecting robust market positioning. * **Normal Product Returns:** Sales returns in Crop Protection remain within historical norms; no abnormal return activity observed in H1. ## C. Registration Costs * **High Export Registration Burden:** Export registrations cost significantly more than domestic due to **five-batch development** and stringent compliance requirements. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Target FY26:** **₹1,000 Cr** (full-year) · **₹565 Cr** achieved in H1 FY26 * **Long-Term Revenue Target:** **₹3,000 Cr** by FY30–31 ## B. FY26 Revenue & Growth Trajectory * **On Track to Deliver FY26 Guidance:** Full-year revenue target of ₹1,000 Cr remains firm, with strong H1 execution and recovery in both export and domestic markets providing confidence. * **Robust Momentum into FY27:** Management expects **at least 20% YoY growth** on both stand-alone and consolidated bases, implying a FY27 revenue run rate of **~₹1,200–1,300 Cr**. * **Near-Term Product Revival:** Resumption of **Pretilachlor and intermediate sales** from Q3/FY27 onward expected to contribute **₹250 Cr+** in revenue. ## C. Long-Term Roadmap & Strategic Enablers * **Clear Path to ₹3,000 Cr by FY31:** Long-term vision anchored in integrated manufacturing, backward integration, specialty chemistry, and global expansion, with Shalvis playing a key role. * **Self-Funded Growth Model:** Target to be primarily financed through **internal accruals**, with only a **nominal loan (₹100–200 Cr)** anticipated over 4–5 years, keeping leverage conservative. ## D. Capex Execution & Funding * **Capex on Schedule:** ₹52 Cr spent of ₹116 Cr total planned; all projects advancing on time, with contributions expected from next fiscal. * **Funding Flexibility:** While capex prioritized via internal accruals, management open to **evaluating buybacks** subject to capital allocation review.